Yarrow Bioscience, Inc. (YARW)
| Market Cap | 145.15M |
| Revenue (ttm) | n/a |
| Net Income | -283.98M |
| EPS | -66.82 |
| Shares Out | 9.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 229,756 |
| Open | 13.80 |
| Previous Close | 13.60 |
| Day's Range | 13.62 - 15.94 |
| 52-Week Range | 12.39 - 46.95 |
| Beta | 2.13 |
| Analysts | Strong Buy |
| Price Target | 58.00 (+271.8%) |
| Est. Earnings | Nov 20, 2026 |
About YARW
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company’s candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves’ disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for YARW stock is "Strong Buy." The 12-month stock price target is $58.0, which is an increase of 271.80% from the latest price.
News
Yarrow Bioscience initiated with a Buy at Guggenheim
As previously reported, Guggenheim analyst Yatin Suneja initiated coverage of Yarrow Bioscience (YARW) with a Buy rating and $60 price target Yarrow’s lead asset, YB-101, is one of the most…
Yarrow Bioscience initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Yarrow Bioscience (YARW) with a Buy rating and $60 price target
Yarrow Bioscience Announces Participation in November Investor Events
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimm...
Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimm...
Yarrow Bioscience 5.77M share Spot Secondary priced at $26.00
Jefferies, TD Cowen and Guggenheim are acting as joint book running managers for the offering. Offering was priced below last closing price of $28.44.
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimm...
Yarrow Bioscience announces common stock offering, no amount given
Yarrow Bioscience (YARW) announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose,…
Yarrow Bioscience Announces Proposed Underwritten Public Offering
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimm...
Yarrow Bioscience reported Q2 EPS ($2.14)
“The second quarter was highly productive for Yarrow and included the initiation of our Phase 2a/2b clinical trial of YB-101, a potential first-in-class anti-TSHR antibody that represents a highly dif...
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience reports second quarter 2026 financial results and provides a business update.
Yarrow Bioscience initiated with a Buy at BTIG
BTIG initiated coverage of Yarrow Bioscience (YARW) with a Buy rating and $58 price target The firm, which views anti-TSHR antibodies as likely to represent the next chapter of care…
Yarrow Bioscience initiated with a Buy at TD Cowen
TD Cowen analyst Stacy Ku initiated coverage of Yarrow Bioscience (YARW) with a Buy rating. YB-101 is the leading anti-thyroid stimulating hormone receptor in Phase 2a development for Graves’ disease,...
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimm...
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its previously announced special cash dividend (the “Cash Dividend”), ...
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its Board of Directors has approved a reverse stock split of VYNE's com...
VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience
Aggregate cash dividend of an estimated $16.5 million, or an estimated $0.38 per share Aggregate cash dividend of an estimated $16.5 million, or an estimated $0.38 per share
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE”) and Yarrow Bioscience, Inc. (“Yarrow”) today announced that they have entered into a definitive merger agreem...
VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update
Company is progressing its previously initiated strategic review evaluating a range of options to maximize shareholder value, including assessment of internal pipeline opportunities and broader strate...
VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update
BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated th...
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo
Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from Ba...
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202
BRIDGEWATER, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated th...
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update
Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 Expected cash runway into 2H 2026 BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VY...
VYNE Therapeutics Provides Update on VYN202 Program
BRIDGEWATER, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) verbally informed...
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
BRIDGEWATER, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated t...
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update
Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 VYN202 Phase 1b psoriasis trial initiated with results anticipated by year-end 2025 Expected cash runway into 2H 2026 BR...